The most common adverse reaction from omalizumab is injection site in duration, injection site itching, injection site pain and bruising but the package insert contains warnings regarding parasitic infections. While there are no reports of fatal anaphylaxis as a result of omalizumab, some cases have been serious and potentially life-threatening. Therefore, the FDA requires that people receiving omalizumab be monitored in the physician's office for a period of time after their injections.
The patient had not previously reported drug induced anaphylaxis. On omalizumab (on the 23 rd dose) therapy, this patient had laryngeal oedema during a complicated common cold infection with bacterial sinusitis after omalizumab injection.
Systemic steroids (500 mg prednisolone), ketotifen fumarate (1X1), antibiotic and antihistamines (desloratadine, 1X1) were given. Oral antihistaminics and mast cell stabilizing agens used for treatment afterwards. We did not stop omalizumab therapy. We do not suggest omalizumab during the first five days of complicated viral infections such as common cold and bacterial sinus infections.
In conventional thinking the involvement of IgE in mast cell activation requires the cross-linking of FcεRI-bound IgE by antigen or anti-IgE antibodies. In a transcriptome analysis of 8793 genes, sensitization of mast cells with monoclonal IgE alone was found to up regulate 58 genes more than 2-fold compared with their levels in un-sensitized mast cells. These genes included those for cytokines (IL-1β, IL-6, and colony-stimulating factor 1); chemokines (CXCL8, CCL7, CCL4); and chemokine receptors [11] [12] [13] . Omalizumab, which has been conceptualized for treating IgE
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A female patient (aged 58) with severe persistent allergic asthma, on omalizumab therapy had laryngeal oedema during a complicated common cold infection with bacterial sinusitis after omalizumab injection. Systemic steroids, ketotifen fumarate, antibiotic and antihistamines (desloratadine) were given. We did not stop omalizumab therapy. To our knowledge, this is the first time an association between omalizumab use and laryngeal oedema has been documented. In fact we do not know the exact mechanism behind this relationship.
Introduction
Omalizumab, a humanized mAb that binds to the CH3 domain, near the binding site for the high-affinity type-I IgE Fc receptors of human IgE, can neutralize free IgE and inhibit the IgE allergic pathway without sensitizing mast cell and basophils. Omalizumab is a humanized recombinant anti-IgE monoclonal antibody approved for therapeutic use both in adults and in children aged 6-12 years with severe allergic asthma. The coexistence of severe asthma refractory to the conventional pharmacological approach and sensitization to at least one perennial allergen represent the current indications for Omalizumab prescription. Its efficacy and safety as an add-on therapy is sustained by several data coming from both clinical trials and real-life experiences [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] and showing a significant reduction of yearly exacerbation-rate. mediated allergic diseases and approved for treating patients with severe persistent allergic asthma in many countries, can neutralize IgE, impede the IgE allergic pathway, and render mast cells and basophils insensitive activation through IgE/FcεRI. In addition to asthma, omalizumab has been investigated in various other conditions including chronic urticaria, perennial and seasonal allergic rhinitis, pru ritic bullous pemphigoid, latex allergy, peanut allergy, idiopathic anaphylaxis, hyper-IgE syndrome, chronic rhinosinusitis, interstitial cystitis, aspirin sensitivity, mastocytosis, eosinophilic gastroenteritis and atopic dermatitis [14] [15] [16] [17] [18] [19] [20] [21] .
Rhinoviruses, which are the most common cause of virally induced asthma exacerbations, account for much of the burden of asthma in terms of morbidity, mortality, and associated cost. Asthmatic epithelial cells have an increased intrinsic capacity for expression of a pro-type 2 cytokine in response to a viral infection, and IL-25 is a key mediator of asthma exacerbations of pulmonary inflammation [22] [23] [24] [25] . To our knowledge, this is the first time, an association between omalizumab use and laryngeal oedema has been documented. Although we do not know the exact mechanism behind this relationship.
Conclusion
To the best of our knowledge, this is the first case. We do not suggest omalizumab during the first five days of complicated viral infections and bacterial sinus infections. We also believe that complicated viral infections may also have an important role in laryngeal oedema. Further studies are needed to investigate. The prescribing information might have been revised based on post marketing surveillance data and reported such cases indicating that different side effects may occur beyond 2 hours after the injection.
